Lecigon

Entacapone/Levodopa/Carbidopa, the active ingredient in Lecigon, is a combination (MAO‑B inhibitor, DOPA decarboxylase inhibitor, dopamine precursor) presented as a tablet for intestinal use. It is indicated for the management of Parkinson’s disease in adults, helping to improve motor function by increasing central dopamine levels and is used as part of a comprehensive therapy regimen.

GNH USA supplies Lecigon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assured manufacturing and distribution networks across Europe, Asia and the Americas.

Lecigon, a combination antiparkinson agent, is used to manage symptoms of Parkinson’s disease. - Parkinson's disease (motor symptoms): improves bradykinesia, rigidity and tremor. - Parkinson's disease (wearing‑off phenomenon): reduces the frequency and duration of “off” periods. - Parkinson's disease (fluctuating response): stabilizes levodopa plasma levels to lessen motor fluctuations.

Lecigon may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools often occurring early in therapy. - Dizziness: transient light‑headedness, especially when standing. - Dry mouth: reduced salivation leading to throat discomfort. - Hallucinations: visual disturbances, particularly in older patients. - Confusion: cognitive changes that may affect concentration.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever and rigidity. - Severe hypotension: marked drop in blood pressure causing fainting. - Hepatic dysfunction: abnormal liver enzymes indicating possible liver injury. - Seizures: rare occurrence of convulsions.

When prescribing Lecigon, clinicians should consider several precautionary measures to ensure safe use. - Assess renal function: adjust therapy in patients with severe renal impairment. - Monitor hepatic enzymes: entacapone may affect liver function, requiring periodic testing. - Evaluate cardiovascular status: watch for orthostatic hypotension, especially in the elderly. - Review psychiatric history: dopamine‑related agents can exacerbate psychosis or hallucinations. - Avoid abrupt discontinuation: gradual tapering reduces risk of withdrawal symptoms. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Lecigon can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis when combined. - Anticholinergic drugs: may mask Parkinsonian symptoms, reducing therapeutic benefit. - CNS depressants (e.g., opioids, benzodiazepines): increase sedation and dizziness.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood pressure‑lowering effect. - SSRIs and SNRIs: potential for serotonin syndrome when combined with MAO‑B inhibition. - Iron supplements: may reduce levodopa absorption; separate dosing by at least 2 hours.